The role involves preparing and executing the launch of two new products, Avutometinib and Defactinib, for low grade serous ovarian cancer.
Base: $170,000 - $200,000 annually; Bonus/Equity: Potential start-up equity program available; Benefits: Health, Dental, Vision, 401k, Tuition Assistance, Discretionary Time Off
Must-have
Nice-to-have
Not specified